Evidence map›Paper›PMID 31481464›Full record

ArticleThe Journal of biological chemistry2019

Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.

Victor Clausse, Dingyin Tao, Subrata Debnath, Yuhong Fang, Harichandra D Tagad, Yuhong Wang, Hongmao Sun, Christopher A LeClair, Sharlyn J Mazur, Kelly Lane and 11 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Use ofFrontiers in toxicology · 2024
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 2 countries.

Victor ClausseSynthetic Bioactive Molecules Section, Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, Bethesda, Maryland 20892.
Dingyin TaoNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850.ORCID 0000-0001-6531-2740
Subrata DebnathLaboratory of Cell Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892.
Yuhong FangNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850.ORCID 0000-0001-6742-5677
Harichandra D TagadLaboratory of Cell Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892.ORCID 0000-0003-1595-6665
Yuhong WangNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850.
Hongmao SunNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850.
Christopher A LeClairNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850.ORCID 0000-0002-2746-5938
Sharlyn J MazurLaboratory of Cell Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892.ORCID 0000-0002-6378-0791
Kelly LaneImaging Probe Development Center, NHLBI, National Institutes of Health, Rockville, Maryland 20850.
Zhen-Dan ShiImaging Probe Development Center, NHLBI, National Institutes of Health, Rockville, Maryland 20850.
Olga VasalatiyImaging Probe Development Center, NHLBI, National Institutes of Health, Rockville, Maryland 20850.
Rebecca EellsReaction Biology Corporation, 1 Great Valley Parkway, Suite 2, Malvern, Pennsylvania 19355.
Lynn K BakerReaction Biology Corporation, 1 Great Valley Parkway, Suite 2, Malvern, Pennsylvania 19355.
Mark J HendersonNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850.ORCID 0000-0001-8590-7338
Martin R WebbFrancis Crick Institute, 1 Midland Road, London NW1 AT, United Kingdom.
Min ShenNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850.ORCID 0000-0002-8218-0433
Matthew D HallNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850 hallma@mail.nih.gov.ORCID 0000-0002-5073-442X
Ettore AppellaLaboratory of Cell Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892.
Daniel H AppellaSynthetic Bioactive Molecules Section, Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, Bethesda, Maryland 20892.
Nathan P CoussensNational Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850 coussensn@mail.nih.gov.ORCID 0000-0002-3896-7909
National Institutes of Health · USReaction Biology Corporation (United States) · USThe Francis Crick Institute · GB

Funding

Imaging Probe Development CenterZICHL005090 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI SWENSON, ROLF · 2011 to 2025
$22.2M
Regulation and Function of WIP1 Phosphatase and its Role in Tumor CellsZIABC011197 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI APPELLA, ETTORE · 2009 to 2025
$11.5M
qHTS to Identify Activators and Inhibitors of Wip1ZIATR000110 · NCATS · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · PI PATNAIK, SAMARJIT · 2015 to 2025
$1.3M
Chemically Modified Peptide Nucleic AcidsZ01DK031143 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI APPELLA, DANIEL H · 2005 to 2008
$892k
Intramural NIH HHS Z01 DK031143Intramural NIH HHS ZIA BC011197Intramural NIH HHS ZIA TR000110Intramural NIH HHS ZIC HL005090Wellcome Trust FC001211
6 · The paper itself

Abstract

WT P53-Induced Phosphatase 1 (WIP1) is a member of the magnesium-dependent serine/threonine protein phosphatase (PPM) family and is induced by P53 in response to DNA damage. In several human cancers, the WIP1 protein is overexpressed, which is generally associated with a worse prognosis. Although WIP1 is an attractive therapeutic target, no potent, selective, and bioactive small-molecule modulator with favorable pharmacokinetics has been reported. Phosphatase enzymes are among the most challenging targets for small molecules because of the difficulty of achieving both modulator selectivity and bioavailability. Another major obstacle has been the availability of robust and physiologically relevant phosphatase assays that are suitable for high-throughput screening. Here, we describe orthogonal biochemical WIP1 activity assays that utilize phosphopeptides from native WIP1 substrates. We optimized an MS assay to quantify the enzymatically dephosphorylated peptide reaction product in a 384-well format. Additionally, a red-shifted fluorescence assay was optimized in a 1,536-well format to enable real-time WIP1 activity measurements through the detection of the orthogonal reaction product, P

Indexed as

Enzyme ActivatorsHigh-Throughput Screening AssaysHumansPhosphopeptidesProtein Phosphatase 2CSmall Molecule LibrariesSubstrate SpecificityTumor Suppressor Protein p53Enzyme ActivatorsPhosphopeptidesPPM1D protein, humanProtein Phosphatase 2CSmall Molecule LibrariesTP53 protein, humanTumor Suppressor Protein p53assaycancercancer therapyenzyme kineticsfluorescencehigh-throughput screening (HTS)kineticsmass spectrometry (MS)oncogenephosphatasephosphorylationRapidFiretherapeuticsWip1

Identifiers

PMID31481464
PMCPMC6873202
OpenAlexW2971857672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.